Development of monoclonal antibodies to prevent and treat infections from Flaviviruses
Funds research to develop monoclonal antibody therapies for specific Flaviviruses, advancing clinical candidates and EU outbreak preparedness.
Funder: European Commission
Due Dates: April 13, 2027: Full application deadline (single-stage submission)
Funding Amounts: €9–10 million per project; up to 4 grants; typical project duration 3–5 years; 100% funding for eligible costs.
Summary: Supports research to develop monoclonal antibody therapies for the prevention and treatment of infections caused by specific Flaviviruses, advancing EU preparedness for viral outbreaks.
Key Information: Applicants must target only one Flavivirus per proposal; clinical study annex required.
Description
This Horizon Europe call funds collaborative research and innovation projects to develop experimental monoclonal antibodies for the prevention and treatment of emerging or re-emerging infections caused by specific Flaviviruses (Dengue, Tick-borne Encephalitis, Japanese Encephalitis, West Nile Fever, Yellow Fever, or Zika Virus). The scope covers advancing existing prophylactic and therapeutic monoclonal antibody candidates, in vitro and in vivo characterization, risk evaluation (including Antibody-Dependent Enhancement risk), batch production under Good Manufacturing Practices (GMP), and conducting first-in-human clinical safety studies. Projects must focus on a single Flavivirus per proposal and are expected to engage with regulatory authorities, leverage state-of-the-art research infrastructures, and foster the participation of start-ups and SMEs. The aim is to strengthen the EU’s leadership and preparedness in antiviral research and response.
